Millennium Management LLC Buys 743,499 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Millennium Management LLC increased its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 125.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,336,908 shares of the company's stock after purchasing an additional 743,499 shares during the period. Millennium Management LLC owned 2.27% of Pyxis Oncology worth $4,425,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fullcircle Wealth LLC purchased a new position in Pyxis Oncology during the 2nd quarter worth approximately $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $59,000. Cetera Advisors LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $100,000. Schulhoff & Co. Inc. grew its holdings in shares of Pyxis Oncology by 90.9% during the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company's stock valued at $139,000 after acquiring an additional 20,000 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Pyxis Oncology by 56.0% during the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company's stock valued at $193,000 after acquiring an additional 20,901 shares in the last quarter. Institutional investors own 39.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on PYXS shares. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They set a "buy" rating and a $10.00 price target on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $9.00.

Pyxis Oncology Stock Performance

PYXS stock traded up $0.08 during mid-day trading on Friday, hitting $3.23. 334,997 shares of the company were exchanged, compared to its average volume of 626,803. The firm has a market cap of $190.21 million, a P/E ratio of -2.38 and a beta of 1.27. The firm's 50 day simple moving average is $3.53 and its 200 day simple moving average is $3.82. Pyxis Oncology, Inc. has a 1-year low of $1.35 and a 1-year high of $6.85.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. On average, equities research analysts predict that Pyxis Oncology, Inc. will post -1.07 EPS for the current fiscal year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.